It is clear that p53 overexpression (more than 50%) is associated with poor prognosis in DLBCL patients (5-year PFS of DLBCL with p53 expression >50% was 28%; 5-year OS of DLBCL with p53 expression >50% was 46%) (40–46). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.